The first stop for professional medicines advice

Sexual Health Patient Group Direction (PGD) Templates

Jo Jenkins, Specialist Pharmacist (Patient Group Directions) SPS Medicines Use and Safety Division Published Last updated See all updates
Topics: AciclovirCommunity Health ServicesImiquimod · Patient Group DirectionsPodophyllotoxinPrimary CareRaltegravirSexual healthTemplatesTrusts ·

SPS and the British Association of Sexual Health and HIV (BASHH)/British Association of HIV (BHIVA), with the support of specialist stakeholders working within clinical practice, have produced PGD templates for medicines commonly used within sexual health services.

The aim of these templates is to produce a consistent presentation which has been reviewed by specialists within sexual health. They have ensured that the legislative and clinical parameters have been fully considered.

The PGD templates may require local adaptation to reflect local policies, commissioning arrangements etc – the areas of each PGD template requiring local adaptation are highlighted in blue throughout each PGD template.

The PGD templates contain advisory text (highlighted in yellow) intended to support the adoption of the PGD – all text in yellow highlight should be removed from final versions of the PGDs.

Each organisation using these PGD templates must ensure that it is clinically signed by a senior pharmacist, a senior doctor and any other professional group representatives involved in its use and that it is reviewed in line with the organisation’s PGD governance system. The organisation’s governance lead (or nominated deputy) must sign to authorise the PGD on behalf of the authorising organisation to ensure that this document meets legal requirements for a PGD. See SPS website or NICE guidance for further guidance on signatories.

It is intended that these templates will be reviewed and re-released prior to reaching their expiry date. If any relevant changes occur to the product SPC or other guidance then an earlier review will be undertaken. Any decision to locally extend a stated expiry date needs to be locally assessed and agreed as per the organisation’s local policy

The following PGD templates are available:

  • Emtricitabine/tenofovir disoproxil as Pre-Exposure Prophylaxis (PrEP) for the prevention of HIV infection
  • Emtricitabine/tenofovir disoproxil and raltegravir tablets for HIV Post Exposure Prophylaxis (HIV PEP)
  • Azithromycin for the treatment of uncomplicated genital Chlamydia trachomatis and non-gonococcal/non-specific urethritis/Mycoplasma genitalium
  • Doxycycline for the treatment of uncomplicated genital chlamydia trachomatis and non-gonococcal/non-specific urethritis
  • Metronidazole for treatment of Bacterial vaginosis and trichomonas vaginalis
  • Administration of ceftriaxone injection (reconstituted with lidocaine 1% w/v injection) by intramuscular (IM) injection for the treatment of uncomplicated Neisseria gonorrhoeae infection
  • Clotrimazole cream for symptomatic treatment of vulvo-vaginal candidiasis
  • Clotrimazole pessaries for treatment of vulvo-vaginal candidiasis
  • Fluconazole for treatment of vulvo-vaginal candidiasis
  • Aciclovir for the treatment of genital herpes simplex virus (HSV) infections
  • Imiquimod 5% w/w cream for the treatment of external anogenital warts
  • Podophyllotoxin 0.15% w/w cream or 0.5% w/v solution for the treatment of external anogenital warts

The wider programme work plan can be found on the Medicines Do Once Programme page which can be found here.

SPS have also developed PGD templates for use in reproductive health services which can be found at the link below.

 

Attachments

Change history

  1. PrEP PGD template updated (V1.2) - format changes to inclusion criteria only
  2. PGD added - emtricitabine/tenofovir disoproxil and raltegravir tablets for HIV Post Exposure Prophylaxis (HIV PEP)
  1. New PGD templates for aciclovir, imiquimod and podophyllotoxin published
  1. PrEP PGD template updated (V1.1) - inclusion criteria amended in line with updated BHIVA/BASHH/BIA Adult HIV Testing guidelines 2020.
  1. Published